Clinical trials: Adjuvant
Larynx, Lip
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
The purpose of this study is to investigate other drugs that may be combined with radiation to treat cancer. The study focuses on determining whether a combination of durvalumab with radiation can both improve cure rate and at…
- Conditions
- Larynx, Lip, Oral Cancer, Digestive Organs--Diseases
- Trial name
- NCT03529422
- Testing
- Durvalumab, Intensity Modulated Radiotherapy Treatments
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lung Cancer, Esophageal Cancer
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Background: Certain types of lung, esophageal, or thymic cancers and mesotheliomas have specific antigens (protein molecules) on their surfaces.
- Conditions
- Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma
- Trial name
- NCT01143545
- Testing
- Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
SARS-CoV-2 Infection, COVID-19
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
This is a study to evaluate the efficacy, immune response, and safety of a coronavirus disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in adults aged 18-84 years in the United Kingdom.
- Trial name
- NCT04583995
- Testing
- SARS-CoV-2 rS/Matrix M1-Adjuvant, Licensed seasonal influenza vaccine
- Where
- 33 sites in United Kingdom
- Volunteers
- 15,185 people, healthy volunteers welcome
- Sponsor
- Novavax
Tuberculosis
A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)
The study has the following objectives: Primary objective To evaluate the safety profile of an adjuvanted TB subunit vaccine administered in different antigen/adjuvant formulations at 0 and 2 months Secondary objective To…
- Trial name
- THYB-03 (NCT01049282)
- Testing
- Antigen (Ag85B-ESAT-6), Antigen (Ag85B-ESAT-6) with adjuvant (IC31)
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Lung Cancer
Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy is more effective than no further treatment for non-small…
- Trial name
- NCT00002583
- Testing
- cisplatin, vinorelbine ditartrate
- Where
- 155 sites in United States, Canada
- Volunteers
- 482 people
- Sponsor
- NCIC Clinical Trials Group
Pain
Effectiveness of Perineural Clonidine as an Adjuvant With Ropivacaine for Popliteal Nerve Block in Patients Undergoing Foot and Ankle Surgery
Nerve blocks are used to decrease the amount of pain you have after surgery. We are asking you to take part in a research study.
- Trial name
- NCT01986751
- Testing
- Clonidine, ropivacaine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Alabama at Birmingham
Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
This is an interventional, prospective multicenter, open-label, phase II study in patients after curative surgery for BTC in a classic adjuvant situation, consisting of a two arm feasibility pilot part with a randomized…
- Conditions
- Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma
- Trial name
- NCT05239169
- Testing
- Durvalumab, Tremelimumab, Capecitabine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Gastric Cancer
Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells
The purpose of this study is to assess the efficacy and safety of apatinib as maintenance therapy after adjuvant chemotherapy in progressive gastric cancer patients with positive exfoliative cancer cells.
- Trial name
- NCT02510469
- Testing
- Apatinib
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Hebei Medical University
Cervical Cancer, Immunochemotherapy
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
- Trial name
- NCT07167160
- Testing
- Camrelizumab combined with chemotherapy
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
ctDNA, Colorectal Cancer (CRC)
Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer
This study will utilize ctDNA methylation detection to evaluate patients with stage I or low-risk stage II colorectal cancer who are ctDNA-positive one month after surgery.
- Conditions
- ctDNA, Colorectal Cancer (CRC), Adjuvant Chemotherapy
- Trial name
- CLEAR-01 (NCT07562659)
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Adenoid Cystic Carcinoma, Sinonasal Carcinoma
SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma
Background: Sinonasal adenoid cystic carcinoma (ACC) is a rare type of cancer that starts in the nasal cavity or sinuses. Although surgery can remove the tumor, doctors often recommend radiation therapy after surgery to reduce…
- Trial name
- SPARE-1st (NCT07563088)
- Testing
- Postoperative Radiotherapy, Observation
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Norovirus Gastroenteritis
Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant…
- Trial name
- NCT02868073
- Testing
- VXA-G1.1-NN (high dose) Oral Vaccine Tablet, VXA-G1.1-NN (low dose) Oral Vaccine Tablet
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Vaxart
Norovirus Gastroenteritis
Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers
A Phase 1b, randomized, double-blind, dose-ranging trial to determine the safety of different dosing regimens an adenoviral-vector based norovirus vaccine (VXA-G1.1-NN) expressing GI.1 VP1 and dsRNA adjuvant administered orally…
- Trial name
- NCT03125473
- Testing
- VXA-G1.1-NN Oral Vaccine
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Vaxart
Carcinoma, Non-Small-Cell Lung, Chemotherapy, Adjuvant
Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection
This study will establish a multi-center, prospective registration database. The included population are stage II and IIIA NSCLC patients undergoing R0 resection and will be scheduled for adjuvant chemotherapy.
- Trial name
- NCT03479294
- Testing
- Shenlingcao Oral Liquid
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1…
- Trial name
- NCT03727880
- Testing
- Pembrolizumab, Defactinib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Lei Zheng
Resectable Stage II-IIIa NSCLC
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
This is a randomized, open-label, multi-center Phase III clinical study aimed at head-to-head evaluating the clinical efficacy of three immunotherapy strategies, namely perioperative immunotherapy, neoadjuvant immunotherapy, and…
- Trial name
- ECTOP-1030 (NCT07554846)
- Testing
- Peroperative immunotherapy, Neoadjuvant immunotherapy, Adjuvant immunotherapy
- Where
- China
- Volunteers
- 759 people
- Sponsor
- Fudan University
Gastric Cancer
Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection
The purpose of this study is to determine whether raltitrexed concurrent with IMRT is safe, tolerable and effective in the treatment for patients with local-advanced gastric cancer after D0/D1 radical resection.
- Trial name
- NCT03392103
- Testing
- Raltitrexed, postoperative radiotherapy
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Zhongnan Hospital
Breast Cancer
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy.
- Trial name
- BRE-08 (NCT06085742)
- Testing
- Cyclophosphamide, Methotrexate, Capecitabine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Illinois at Chicago
Pseudomyxoma Peritonei
Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients
This is a phase II, mono institutional, non comparative study, evaluating adjuvant capecitabine in patients affected by KRAS mutated Pseudomyxoma peritonei treated with cytoreductive surgery and HIPEC.
- Trial name
- ACAPP (NCT05321329)
- Testing
- Capecitabine
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Breast Cancer
An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy
The aim of this study is to evaluate benefits of the app in breast cancer patients receiving the docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.
- Trial name
- NCT05258461
- Testing
- use of a smartphone app for adverse event management, conventional adverse event management
- Volunteers
- 108 people
- Sponsor
- Peking Union Medical College Hospital